Related Experiment Video
Updated: Nov 16, 2025
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
The Survival Benefit of Postoperative Bacterial Infections in Patients With Glioblastoma Multiforme: Myth or Reality?
Syed Faraz Kazim1, Erick Martinez2, Tyler J Hough3
1Department of Neurosurgery, University of New Mexico Hospital (UNMH), Albuquerque, NM, United States.
Abstract:
Glioblastoma multiforme (GBM), the most common malignant brain tumor, universally carries a poor prognosis. Despite aggressive multimodality treatment, the median survival is ~18-20 months, depending on molecular subgroups. A long history of observations suggests antitumor effects of bacterial infections against malignant tumors. The present review summarizes and critically analyzes the clinical data providing evidence for or against the survival benefit of post-operative bacterial infections in GBM patients. Furthermore, we explore the probable underlying mechanism(s) from basic science studies on the topic. There are plausible explanations from immunobiology for the mechanism of the "favorable effect" of bacterial infections in GBM patients. However, available clinical literature does not provide a definitive association between postoperative bacterial infection and prolonged survival in GBM patients. The presently available, single-/multi-center and national database retrospective case-control studies on the topic provide conflicting results. A prospective randomized study on the subject is clearly not possible. Immunobiology literature supports development of genetically modified bacteria as part of multimodal regimen against GBM.
Insights
Postoperative bacterial infections in glioblastoma multiforme (GBM) patients show potential antitumor effects, but clinical data do not definitively link them to improved survival. Further research into immunobiology mechanisms is warranted.
Area of Science:
- Neuro-oncology
- Immunology
- Infectious Disease
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis, often with median survival around 18-20 months.
- Historical observations suggest bacterial infections may possess antitumor properties against malignant neoplasms.
- The potential benefits of post-operative bacterial infections in GBM patients remain an area of interest.
Purpose of the Study:
- To critically review and analyze clinical data on the survival benefit of post-operative bacterial infections in GBM patients.
- To explore potential underlying immunobiological mechanisms responsible for any observed "favorable effect" of bacterial infections.
- To assess the current evidence for and against a link between infection and prolonged survival in GBM.
Main Methods:
- Systematic review and critical analysis of existing clinical literature.
- Examination of basic science studies investigating the immunobiology of bacterial infections and cancer.
- Evaluation of retrospective case-control studies from single/multi-center and national databases.
Main Results:
- While immunobiology offers plausible explanations for potential antitumor effects, clinical data do not conclusively establish a survival benefit from post-operative bacterial infections in GBM.
- Retrospective studies yield conflicting results, lacking definitive association between infection and prolonged survival.
- Prospective randomized trials are deemed infeasible for this specific research question.
Conclusions:
- The current clinical evidence is insufficient to confirm that post-operative bacterial infections improve survival in glioblastoma multiforme patients.
- Immunobiology research supports the potential of engineered bacteria as a future therapeutic strategy for GBM.
- Further investigation into the complex interplay between infection and the tumor microenvironment is needed.
